Zobrazeno 1 - 10
of 151
pro vyhledávání: '"J, van der Lelie"'
Autor:
Gert J. Ossenkoppele, C. M. Slaper, J. Van Der Lelie, L. L. M. Thomas, M. J. Wijngaarden, P. C. Huijgens
Publikováno v:
Hematological Oncology. 9:245-251
Thirty patients with high-grade malignant lymphoma were treated with ifosfamide-VP16213-methotrexate (IMVP-16) combination chemotherapy after failing to respond completely or after relapsing on CHOP-like therapy. Responders to the salvage therapy sub
Autor:
B. Lowenberg, R. Neuwirtova, C. M. Segeren, H. Dohner, H.M Lokhorst, R. Willemze, P. Sonneveld, Stefan Suciu, M. Beksac, H. Gerhartz, P. Weijermans, J van der Lelie, G. Solbu
Publikováno v:
British Journal of Haematology. 115:895-902
Patients with multiple myeloma (MM) refractory to alkylating agents frequently express P-glycoprotein (Pgp), which is associated with the multidrug resistance (MDR) phenotype. We have conducted a randomized phase II/III study of the MDR reversal agen
Autor:
J. Van Der Lelie, M. H. J. Van Oers, L. L. M. Thomas, E. S. Louwerse, A. E. G. K. Von Dem Borne
Publikováno v:
European Journal of Haematology. 56:95-97
Autor:
P. W. Wijermans, Geg Verhoef, Wlj van Putten, J van der Lelie, S Daenen, B. Lowenberg, Pieter Sonneveld, B. van der Holt, Gert J. Ossenkoppele, Leo F. Verdonck
Publikováno v:
Leukemia, 13, 1207-1213. Nature Publishing Group
Leukemia, 13(8), 1207-1213. Nature Publishing Group
Leukemia, 13(8), 1207-1213. Nature Publishing Group
The purpose of this study was to determine the safety and efficacy of filgrastim as an adjunct to induction and consolidation chemotherapy in poor risk patients with myelodysplastic syndrome (MDS). Filgrastim was given both during and after chemother
Autor:
Lucien A. Aarden, S. O. Warnaar, H. J. A. M. Rensink, J. Van Der Lelie, H. C. T. Van Zaanen, M. H. J. Van Oers, H. M. Lokhorst
Publikováno v:
British Journal of Haematology. 102:783-790
Interleukin 6 plays a key role in the pathogenesis of multiple myeloma (MM). Therefore we conducted a phase I dose-escalating study with chimaeric monoclonal anti-IL6 antibodies (cMab) in MM patients resistant to second-line chemotherapy. The cMab (C
Autor:
A. W. Dekker, G Ossenkoppele, Peter C. Huijgens, J van der Lelie, Leo F. Verdonck, Roelof Willemze, M. B. Van't Veer, Pieter Sonneveld, H. C. Schouten, Bob Löwenberg, W. L. J. Van Putten, W. Sizoo, H. L. Haak
Publikováno v:
Journal of Clinical Oncology. 15:476-482
PURPOSE To investigate the value of intensive consolidation chemotherapy not followed by maintenance therapy in adult acute lymphoblastic leukemia (ALL). MATERIALS AND METHODS A multicenter phase II trial was conducted in 130 adult patients with ALL
Publikováno v:
European Journal of Clinical Microbiology & Infectious Diseases
European journal of clinical microbiology & infectious diseases, 12(10), 750-755. Springer Verlag
European journal of clinical microbiology & infectious diseases, 12(10), 750-755. Springer Verlag
The efficacy of penicillin G was evaluated in the prevention of infections caused by streptococci in patients receiving remission induction or intensive consolidation treatment for acute myeloid leukaemia. Between 1980 and 1988, 29 episodes of strept
Autor:
J. van der Lelie, H. C. T. van Zaanen
Publikováno v:
Cancer. 69:1710-1713
The case is reported of a patient with acute myeloid leukemia with severe right-sided congestive heart failure that responded to treatment with thiamine. Leukocytes cells contain relatively high concentrations of thiamine-dependent enzymes compared w
Autor:
A V M B, Schattenberg, Harry C, Schouten, Leo F, Verdonck, Roel, Willemze, J, van der Lelie, Peter C, Huijgens, Gustaaf W, van Imhoff, Anja, van Biezen, Ronaldt, Brand, A, Hagenbeek, Theo, de Witte, Jan J, Cornelissen
Publikováno v:
Nederlands tijdschrift voor geneeskunde. 153(9)
Autor:
J, van der Lelie
Publikováno v:
Nederlands tijdschrift voor geneeskunde. 152(16)
Erythropoietin has been shown to shorten survival in cancer patients under certain circumstances. Possible mechanisms are an increase in thrombotic events, tumour progression, and induction of angiogenesis. The FDA advises its use in oncology only as